Drug
Bifeprunox clinical trials
Also written DU 127090.
How studies write it
Studies that test it under each name
Studies by the year they started
19 studies that test it; most in 2005 (9)
| Year | Studies |
|---|---|
| 2005 | 9 |
| 2006 | 5 |
| 2007 | 3 |
| 2008 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 19 · Other 0
Solvay Pharmaceuticals (9) · Wyeth is now a wholly owned subsidiary of Pfizer (7) · H. Lundbeck A/S (3)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses bifeprunox is read from its arms, and is right about nine times in ten.
Testing it · 19
- Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's TypeTerminatedPhase 3Solvay PharmaceuticalsNCT00160147Written as bifeprunox
- Bifeprunox in the Treatment of SchizophreniaCompletedPhase 3Solvay PharmaceuticalsNCT00193713Written as bifeprunox
- Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schizophrenia or Bipolar DisorderCompletedPhase 2Solvay PharmaceuticalsNCT00139919Written as Bifeprunox
- Twice Daily Titration Study of Bifeprunox in Subjects With SchizophreniaCompletedPhase 2Solvay PharmaceuticalsNCT00139906Written as Bifeprunox
- To Evaluate the Impact of Treatment Interruption on Re-initiation of BifeprunoxCompletedPhase 2Solvay PharmaceuticalsNCT00141479Written as Bifeprunox
- PK Effects of Bifeprunox & Valproate in Bipolar ICompletedPhase 2Solvay PharmaceuticalsNCT00141505Written as Bifeprunox
- Bifeprunox Extension to Extension Study in Patients With SchizophreniaTerminatedPhase 3H. Lundbeck A/SNCT00861497Written as Bifeprunox
- Patient-reported Outcomes in the Treatment of SchizophreniaCompletedPhase 3Solvay PharmaceuticalsNCT00230828Written as bifeprunox
- Study Evaluating Bifeprunox in Bipolar DepressionCompletedPhase 3Wyeth is now a wholly owned subsidiary of PfizerNCT00134459Written as Bifeprunox
- Study Evaluating Bifeprunox in Patients With Schizophrenia.TerminatedPhase 3Wyeth is now a wholly owned subsidiary of PfizerNCT00366327Written as Bifeprunox
- Study Comparing Bifeprunox to Risperidone in Treatment of Outpatients With Schizophrenia With Weight as Primary EndpointTerminatedPhase 3Wyeth is now a wholly owned subsidiary of PfizerNCT00366704Written as bifeprunox
- Efficacy of Bifeprunox in Patients With SchizophreniaTerminatedPhase 3H. Lundbeck A/SNCT00704509Written as Bifeprunox
- Efficacy of Bifeprunox in Patients With SchizophreniaTerminatedPhase 3H. Lundbeck A/SNCT00658645Written as Bifeprunox
- Study Evaluating the Tolerability of Bifeprunox in Healthy SubjectsCompletedPhase 1Wyeth is now a wholly owned subsidiary of PfizerNCT00581451Written as bifeprunox
- Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic PatientsTerminatedPhase 3Solvay PharmaceuticalsNCT00396214Written as Bifeprunox
- Bifeprunox in the Treatment of SchizophreniaCompletedPhase 3Solvay PharmaceuticalsNCT00193687Written as bifeprunox
- Study Comparing the Affect of Bifeprunox Vs Olanzapine on Weight During the Treatment of Outpatients With Schizophrenia.CompletedPhase 3Wyeth is now a wholly owned subsidiary of PfizerNCT00380224Written as bifeprunox, olanzapine
- Open Label Extension Study of BifeprunoxCompletedPhase 3Wyeth is now a wholly owned subsidiary of PfizerNCT00366171Written as Bifeprunox
- Study Evaluating Bifeprunox in Bipolar DepressionCompletedPhase 3Wyeth is now a wholly owned subsidiary of PfizerNCT00245973Written as Bifeprunox
Codes
What other systems call bifeprunox · ClinicalTrials.gg INT004908
- MeSH (NLM) C509981bifeprunoxOne source NLM
- UNII (FDA) AP69E83Z79BIFEPRUNOXConfirmed FDA, NLM, Wikidata
- Wikidata Q4904729bifeprunoxConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C65262BifeprunoxOne source FDA
- DrugBank DB04888One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C509981 | bifeprunox | One source NLM |
| UNII (FDA) | AP69E83Z79 | BIFEPRUNOX | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q4904729 | bifeprunox | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C65262 | Bifeprunox | One source FDA |
| DrugBank | DB04888 | — | One source Wikidata |
Also registered as bifeprunox mesylate (UNII 8F018D8L02).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.